VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
59 hedge funds and large institutions have $52.8M invested in Viracta Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
6% less funds holding
Funds holding: 63 → 59 (-4)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
Holders
59
Holding in Top 10
1
Calls
$627K
Puts
$235K
Top Buyers
| 1 | +$4.21M | |
| 2 | +$877K | |
| 3 | +$620K | |
| 4 |
BlackRock
New York
|
+$509K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$106K |
Top Sellers
| 1 | -$720K | |
| 2 | -$703K | |
| 3 | -$367K | |
| 4 |
HLA
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
|
-$151K |
| 5 |
LSA
Leonteq Securities AG
Zurich,
Switzerland
|
-$116K |